RxDoctor Payments Data

Ejodamen Shobowale, DPM

Foot & Ankle Surgery · Houston, TXNPI 1083029060

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Stryker at 45.6% of the total. Reporting peaked in 2023 at $2,715 and has fallen 79.6% since, to $554 in 2025.

$11,102in general payments, 2019–2025

Across 180 payments — averaging $61.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$5K
  • Kerecis Limited$2K
  • Arthrosurface Incorporated$892
  • Integra Lifesciences Corporation$527
  • Sanara Medtech Inc.$408
  • Paratek Pharmaceuticals, Inc.$365
  • plus $2K from 24 others
$26,015in research payments, 2019–2025

Across 9 payments — averaging $2890.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$26K

What the payments were for

  • Travel & lodging$4,74243%
  • Food & beverage$6,34557%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,102 in reported general payments places this provider in the 75th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas →

Medicare billing

Part B allowed, 2024
$127,613
Medicare patients
102
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox91$2,425
Ketoconazole92$1,677
Terbinafine Hcl58$378
Ammonium Lactate23$248
Cephalexin34$127
Methylprednisolone20$108
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$74
Ibuprofen23$73
Mupirocin17$66
Gabapentin16$28
Meloxicam16$18

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →